Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by ValuEngine

ValuEngine downgraded shares of Protagonist Therapeutics (NASDAQ:PTGX) from a hold rating to a sell rating in a research note released on Tuesday, ValuEngine reports.

A number of other analysts have also recently issued reports on the company. HC Wainwright set a $23.00 target price on Protagonist Therapeutics and gave the stock a buy rating in a research note on Friday, August 2nd. Zacks Investment Research cut Protagonist Therapeutics from a buy rating to a hold rating in a research note on Thursday, November 14th. Svb Leerink reissued an outperform rating on shares of Protagonist Therapeutics in a research note on Tuesday, August 13th. BidaskClub cut Protagonist Therapeutics from a buy rating to a hold rating in a research note on Saturday, November 9th. Finally, Nomura reissued a buy rating and set a $29.00 target price on shares of Protagonist Therapeutics in a research note on Sunday, August 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $19.60.

NASDAQ PTGX traded down $0.59 during trading hours on Tuesday, reaching $9.54. 11,841 shares of the company’s stock were exchanged, compared to its average volume of 234,309. The company’s 50-day moving average is $11.59 and its two-hundred day moving average is $11.91. Protagonist Therapeutics has a one year low of $5.49 and a one year high of $16.67. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.68 and a current ratio of 4.68. The company has a market capitalization of $289.48 million, a price-to-earnings ratio of -5.59 and a beta of 1.74.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.10. Protagonist Therapeutics had a negative return on equity of 74.86% and a negative net margin of 209.02%. The business had revenue of $4.14 million during the quarter, compared to analysts’ expectations of $5.75 million. Research analysts predict that Protagonist Therapeutics will post -2.99 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in PTGX. Meeder Asset Management Inc. boosted its position in Protagonist Therapeutics by 1,433.3% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,450 shares of the company’s stock worth $41,000 after acquiring an additional 3,225 shares during the last quarter. Rhumbline Advisers boosted its position in Protagonist Therapeutics by 20.7% during the 3rd quarter. Rhumbline Advisers now owns 15,540 shares of the company’s stock worth $187,000 after acquiring an additional 2,662 shares during the last quarter. Algert Global LLC boosted its position in Protagonist Therapeutics by 48.0% during the 2nd quarter. Algert Global LLC now owns 15,517 shares of the company’s stock worth $188,000 after acquiring an additional 5,030 shares during the last quarter. Marshall Wace LLP acquired a new position in Protagonist Therapeutics during the 2nd quarter worth approximately $216,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Protagonist Therapeutics by 63.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 19,486 shares of the company’s stock worth $236,000 after acquiring an additional 7,586 shares during the last quarter. 71.27% of the stock is owned by hedge funds and other institutional investors.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Recommended Story: Real Estate Investment Trust (REIT) ETF

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.